Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 111

1.

Response to "Do different treatment strategies of galcanezumab have similar effect on migraine?"

Goadsby PJ, Terwindt GM, Ruff DD, Ford JH, Tockhorn-Heidenreich A, Stauffer VL, Govindan S, Aurora SK.

Eur J Neurol. 2020 Feb 12. doi: 10.1111/ene.14168. [Epub ahead of print]

PMID:
32052515
2.

Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: Results from 3-month double-blind treatment.

Dodick DW, Goadsby PJ, Lucas C, Jensen R, Bardos JN, Martinez JM, Zhou C, Aurora SK, Yang JY, Conley RR, Oakes T.

Cephalalgia. 2020 Feb 12:333102420905321. doi: 10.1177/0333102420905321. [Epub ahead of print]

PMID:
32050782
3.

Systematic Review: Acupuncture vs Standard Pharmacological Therapy for Migraine Prevention.

Zhang N, Houle T, Hindiyeh N, Aurora SK.

Headache. 2020 Feb;60(2):309-317. doi: 10.1111/head.13723. Epub 2019 Dec 24. Review.

PMID:
31872864
4.

Evaluation of Cardiovascular Outcomes in Adult Patients With Episodic or Chronic Migraine Treated With Galcanezumab: Data From Three Phase 3, Randomized, Double-Blind, Placebo-Controlled EVOLVE-1, EVOLVE-2, and REGAIN Studies.

Oakes TM, Kovacs R, Rosen N, Doty E, Kemmer P, Aurora SK, Camporeale A.

Headache. 2020 Jan;60(1):110-123. doi: 10.1111/head.13684. Epub 2019 Nov 13.

PMID:
31721185
5.

Rapid Onset of Effect of Galcanezumab for the Prevention of Episodic Migraine: Analysis of the EVOLVE Studies.

Detke HC, Millen BA, Zhang Q, Samaan K, Ailani J, Dodick DW, Aurora SK.

Headache. 2020 Feb;60(2):348-359. doi: 10.1111/head.13691. Epub 2019 Nov 11.

PMID:
31710104
6.

Efficacy of galcanezumab in patients with episodic migraine and a history of preventive treatment failure: results from two global randomized clinical trials.

Ruff DD, Ford JH, Tockhorn-Heidenreich A, Stauffer VL, Govindan S, Aurora SK, Terwindt GM, Goadsby PJ.

Eur J Neurol. 2019 Nov 6. doi: 10.1111/ene.14114. [Epub ahead of print]

PMID:
31692188
7.

Positive response to galcanezumab following treatment failure to onabotulinumtoxinA in patients with migraine: post hoc analyses of three randomized double-blind studies.

Ailani J, Pearlman E, Zhang Q, Nagy AJ, Schuh K, Aurora SK.

Eur J Neurol. 2020 Mar;27(3):542-549. doi: 10.1111/ene.14102. Epub 2019 Dec 10.

PMID:
31595600
8.

Predicting initiation of preventive migraine medications: exploratory study in a large U.S. medical claims database.

Ford JH, Schroeder K, Buse DC, Joshi S, Gelwicks S, Foster SA, Aurora SK.

Curr Med Res Opin. 2020 Jan;36(1):51-61. doi: 10.1080/03007995.2019.1657716. Epub 2019 Sep 9.

PMID:
31422701
9.

Approvals and indications of CGRP antibodies.

Nichols R, Detke HC, Hundemer HP, Aurora SK.

Lancet Neurol. 2019 Aug;18(8):718. doi: 10.1016/S1474-4422(19)30229-7. No abstract available.

PMID:
31301747
10.

Trial of Galcanezumab in Prevention of Episodic Cluster Headache.

Goadsby PJ, Dodick DW, Leone M, Bardos JN, Oakes TM, Millen BA, Zhou C, Dowsett SA, Aurora SK, Ahn AH, Yang JY, Conley RR, Martinez JM.

N Engl J Med. 2019 Jul 11;381(2):132-141. doi: 10.1056/NEJMoa1813440.

PMID:
31291515
11.

Two randomized migraine studies of galcanezumab: Effects on patient functioning and disability.

Ford JH, Ayer DW, Zhang Q, Carter JN, Leroux E, Skljarevski V, Aurora SK, Tockhorn-Heidenreich A, Lipton RB.

Neurology. 2019 Jul 30;93(5):e508-e517. doi: 10.1212/WNL.0000000000007856. Epub 2019 Jul 3.

12.

Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine.

Goadsby PJ, Wietecha LA, Dennehy EB, Kuca B, Case MG, Aurora SK, Gaul C.

Brain. 2019 Jul 1;142(7):1894-1904. doi: 10.1093/brain/awz134.

13.

Efficacy of galcanezumab in patients with chronic migraine and a history of preventive treatment failure.

Ruff DD, Ford JH, Tockhorn-Heidenreich A, Sexson M, Govindan S, Pearlman EM, Wang SJ, Khan A, Aurora SK.

Cephalalgia. 2019 Jul;39(8):931-944. doi: 10.1177/0333102419847957. Epub 2019 May 19.

PMID:
31104507
14.

Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: a post-hoc analysis.

Goadsby PJ, Dodick DW, Martinez JM, Ferguson MB, Oakes TM, Zhang Q, Skljarevski V, Aurora SK.

J Neurol Neurosurg Psychiatry. 2019 Aug;90(8):939-944. doi: 10.1136/jnnp-2018-320242. Epub 2019 Apr 19.

15.

CGRP and the Trigeminal System in Migraine.

Iyengar S, Johnson KW, Ossipov MH, Aurora SK.

Headache. 2019 May;59(5):659-681. doi: 10.1111/head.13529. Epub 2019 Apr 14. Review.

16.

Effect of Galcanezumab Following Treatment Cessation in Patients With Migraine: Results From 2 Randomized Phase 3 Trials.

Stauffer VL, Wang S, Voulgaropoulos M, Skljarevski V, Kovacik A, Aurora SK.

Headache. 2019 Jun;59(6):834-847. doi: 10.1111/head.13508. Epub 2019 Apr 3.

17.

Letter to the editor regarding European Headache Federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention.

Nichols R, Skljarevski V, Dell'Agnello G, Hundemer HP, Aurora SK.

J Headache Pain. 2019 Mar 1;20(1):22. doi: 10.1186/s10194-019-0975-2. No abstract available.

18.
19.

Patient satisfaction, health care resource utilization, and acute headache medication use with galcanezumab: results from a 12-month open-label study in patients with migraine.

Ford JH, Foster SA, Stauffer VL, Ruff DD, Aurora SK, Versijpt J.

Patient Prefer Adherence. 2018 Nov 13;12:2413-2424. doi: 10.2147/PPA.S182563. eCollection 2018.

20.
21.

Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study.

Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK.

Neurology. 2018 Dec 11;91(24):e2211-e2221. doi: 10.1212/WNL.0000000000006640. Epub 2018 Nov 16.

22.

Health Care Utilization and Direct Costs Among Patients Diagnosed with Cluster Headache in U.S. Health Care Claims Data.

Choong CK, Ford JH, Nyhuis AW, Robinson RL, Aurora SK.

J Manag Care Spec Pharm. 2018 Sep;24(9):921-928. doi: 10.18553/jmcp.2018.24.9.921.

23.

Measures of Functioning in Patients With Episodic Migraine: Findings From a Double-Blind, Randomized, Placebo-Controlled Phase 2b Trial With Galcanezumab.

Ayer DW, Skljarevski V, Ford JH, Nyhuis AW, Lipton RB, Aurora SK.

Headache. 2018 Sep;58(8):1225-1235. doi: 10.1111/head.13383. Epub 2018 Aug 14.

PMID:
30106172
24.

Cycling Through Migraine Preventive Treatments: Implications for All-Cause Total Direct Costs and Disease-Specific Costs.

Ford JH, Schroeder K, Nyhuis AW, Foster SA, Aurora SK.

J Manag Care Spec Pharm. 2019 Jan;25(1):46-59. doi: 10.18553/jmcp.2018.18058. Epub 2018 Jul 25.

25.

A Real-World Analysis of Migraine: A Cross-Sectional Study of Disease Burden and Treatment Patterns.

Ford JH, Jackson J, Milligan G, Cotton S, Ahl J, Aurora SK.

Headache. 2017 Nov;57(10):1532-1544. doi: 10.1111/head.13202. Epub 2017 Oct 6.

PMID:
28984356
26.

Economics of Inhaled Oxygen Use as an Acute Therapy for Cluster Headache in the United States of America.

O'Brien M, Ford JH, Aurora SK, Govindan S, Tepper DE, Tepper SJ.

Headache. 2017 Oct;57(9):1416-1427. doi: 10.1111/head.13167. Epub 2017 Aug 26.

PMID:
28842974
27.

The impact of onabotulinumtoxinA on severe headache days: PREEMPT 56-week pooled analysis.

Matharu M, Halker R, Pozo-Rosich P, DeGryse R, Manack Adams A, Aurora SK.

J Headache Pain. 2017 Dec;18(1):78. doi: 10.1186/s10194-017-0784-4. Epub 2017 Aug 1.

28.

Clinical Characteristics and Treatment Patterns Among Patients Diagnosed With Cluster Headache in U.S. Healthcare Claims Data.

Choong CK, Ford JH, Nyhuis AW, Joshi SG, Robinson RL, Aurora SK, Martinez JM.

Headache. 2017 Oct;57(9):1359-1374. doi: 10.1111/head.13127. Epub 2017 Jun 5.

29.

Insights into the Functional Anatomy Behind the PREEMPT Injection Paradigm: Guidance on Achieving Optimal Outcomes.

Blumenfeld AM, Silberstein SD, Dodick DW, Aurora SK, Brin MF, Binder WJ.

Headache. 2017 May;57(5):766-777. doi: 10.1111/head.13074. Epub 2017 Apr 6.

30.

Chronic Migraine: An Update on Physiology, Imaging, and the Mechanism of Action of Two Available Pharmacologic Therapies.

Aurora SK, Brin MF.

Headache. 2017 Jan;57(1):109-125. doi: 10.1111/head.12999. Epub 2016 Dec 2. Review.

31.

A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine.

Voss T, Lipton RB, Dodick DW, Dupre N, Ge JY, Bachman R, Assaid C, Aurora SK, Michelson D.

Cephalalgia. 2016 Aug;36(9):887-98. doi: 10.1177/0333102416653233. Epub 2016 Jun 6.

PMID:
27269043
33.

What the Gut Can Teach Us About Migraine.

Hindiyeh N, Aurora SK.

Curr Pain Headache Rep. 2015 Jul;19(7):33. doi: 10.1007/s11916-015-0501-4. Review.

PMID:
26049770
34.

Improving the detection of chronic migraine: Development and validation of Identify Chronic Migraine (ID-CM).

Lipton RB, Serrano D, Buse DC, Pavlovic JM, Blumenfeld AM, Dodick DW, Aurora SK, Becker WJ, Diener HC, Wang SJ, Vincent MB, Hindiyeh NA, Starling AJ, Gillard PJ, Varon SF, Reed ML.

Cephalalgia. 2016 Mar;36(3):203-15. doi: 10.1177/0333102415583982. Epub 2015 May 22.

35.

Sleep disturbances among pregnant women with history of migraines: A cross-sectional study.

Qiu C, Frederick IO, Sorensen T, Aurora SK, Gelaye B, Enquobahrie DA, Williams MA.

Cephalalgia. 2015 Oct;35(12):1092-102. doi: 10.1177/0333102415570493. Epub 2015 Jan 29.

36.

Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT.

Silberstein SD, Dodick DW, Aurora SK, Diener HC, DeGryse RE, Lipton RB, Turkel CC.

J Neurol Neurosurg Psychiatry. 2015 Sep;86(9):996-1001. doi: 10.1136/jnnp-2013-307149. Epub 2014 Dec 12.

37.

Assessing clinically meaningful treatment effects in controlled trials: chronic migraine as an example.

Dodick DW, Turkel CC, DeGryse RE, Diener HC, Lipton RB, Aurora SK, Nolan ME, Silberstein SD.

J Pain. 2015 Feb;16(2):164-75. doi: 10.1016/j.jpain.2014.11.004. Epub 2014 Nov 15.

PMID:
25464159
38.

Agreement of self-reported physician diagnosis of migraine with international classification of headache disorders-II migraine diagnostic criteria in a cross-sectional study of pregnant women.

Qiu C, Williams MA, Aurora SK, Peterlin BL, Gelaye B, Frederick IO, Enquobahrie DA.

BMC Womens Health. 2013 Dec 13;13:50. doi: 10.1186/1472-6874-13-50.

39.

OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program.

Aurora SK, Dodick DW, Diener HC, DeGryse RE, Turkel CC, Lipton RB, Silberstein SD.

Acta Neurol Scand. 2014 Jan;129(1):61-70. doi: 10.1111/ane.12171. Epub 2013 Sep 20.

40.

Lifetime prevalence and correlates of migraine among women in a pacific northwest pregnancy cohort study.

Frederick IO, Qiu C, Enquobahrie DA, Aurora SK, Peterlin BL, Gelaye B, Williams MA.

Headache. 2014 Apr;54(4):675-85. doi: 10.1111/head.12206. Epub 2013 Aug 28.

41.

OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline.

Silberstein SD, Blumenfeld AM, Cady RK, Turner IM, Lipton RB, Diener HC, Aurora SK, Sirimanne M, DeGryse RE, Turkel CC, Dodick DW.

J Neurol Sci. 2013 Aug 15;331(1-2):48-56. doi: 10.1016/j.jns.2013.05.003. Epub 2013 Jun 19.

PMID:
23790235
42.

Gastric stasis in migraineurs: etiology, characteristics, and clinical and therapeutic implications.

Aurora SK, Papapetropoulos S, Kori SH, Kedar A, Abell TL.

Cephalalgia. 2013 Apr;33(6):408-15. doi: 10.1177/0333102412473371. Epub 2013 Mar 5. Review.

43.

Migraine headache is present in the aura phase: a prospective study.

Hansen JM, Lipton RB, Dodick DW, Silberstein SD, Saper JR, Aurora SK, Goadsby PJ, Charles A.

Neurology. 2012 Nov 13;79(20):2044-9. doi: 10.1212/WNL.0b013e3182749eed. Epub 2012 Oct 31.

44.

Migraine with persistent visual aura.

Evans RW, Aurora SK.

Headache. 2012 Mar;52(3):494-501. doi: 10.1111/j.1526-4610.2012.02103.x. No abstract available.

PMID:
22404709
45.

Randomized, controlled study of telcagepant in patients with migraine and coronary artery disease.

Ho TW, Ho AP, Chaitman BR, Johnson C, Mathew NT, Kost J, Fan X, Aurora SK, Brandes JL, Fei K, Beebe L, Lines C, Krucoff MW.

Headache. 2012 Feb;52(2):224-35. doi: 10.1111/j.1526-4610.2011.02052.x. Epub 2012 Jan 6.

PMID:
22221076
46.

Chronic migraine: a road less travelled.

Aurora SK.

Headache. 2011 Nov-Dec;51(10):1578. doi: 10.1111/j.1526-4610.2011.02023.x. No abstract available.

PMID:
22082430
47.

OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine.

Lipton RB, Varon SF, Grosberg B, McAllister PJ, Freitag F, Aurora SK, Dodick DW, Silberstein SD, Diener HC, DeGryse RE, Nolan ME, Turkel CC.

Neurology. 2011 Oct 11;77(15):1465-72. doi: 10.1212/WNL.0b013e318232ab65. Epub 2011 Sep 28.

PMID:
21956721
48.

Needle-free subcutaneous sumatriptan for triptan users requiring a change in migraine therapy: efficacy and impact on patient-rated functionality, satisfaction, and confidence.

Rothrock JF, Cady RK, Aurora SK, Brandes JL, Myers JA, Fox AW, Farr SJ.

Curr Med Res Opin. 2011 Nov;27(11):2185-91. doi: 10.1185/03007995.2011.619177. Epub 2011 Sep 26.

PMID:
21942531
49.

OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.

Aurora SK, Winner P, Freeman MC, Spierings EL, Heiring JO, DeGryse RE, VanDenburgh AM, Nolan ME, Turkel CC.

Headache. 2011 Oct;51(9):1358-73. doi: 10.1111/j.1526-4610.2011.01990.x. Epub 2011 Aug 29.

PMID:
21883197
50.

Satisfaction with and confidence in needle-free subcutaneous sumatriptan in patients currently treated with triptans.

Cady RK, Aurora SK, Brandes JL, Rothrock JF, Myers JA, Fox AW, Farr SJ.

Headache. 2011 Sep;51(8):1202-11. doi: 10.1111/j.1526-4610.2011.01972.x. Epub 2011 Aug 3.

PMID:
21812775

Supplemental Content

Loading ...
Support Center